182 related articles for article (PubMed ID: 30075728)
1. A policy analysis exploring hepatitis C risk, prevention, testing, treatment and reinfection within Australia's prisons.
Lafferty L; Wild TC; Rance J; Treloar C
Harm Reduct J; 2018 Aug; 15(1):39. PubMed ID: 30075728
[TBL] [Abstract][Full Text] [Related]
2. Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study.
Bretaña NA; Gray RR; Cunningham EB; Betz-Stablein B; Ribeiro R; Graw F; Luciani F; Lloyd AR
Addiction; 2020 May; 115(5):901-913. PubMed ID: 31633853
[TBL] [Abstract][Full Text] [Related]
3. Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries.
Bielen R; Stumo SR; Halford R; Werling K; Reic T; Stöver H; Robaeys G; Lazarus JV
Harm Reduct J; 2018 May; 15(1):25. PubMed ID: 29751763
[TBL] [Abstract][Full Text] [Related]
4. Consensus recommendations on the management of hepatitis C in Australia's prisons.
Winter RJ; Sheehan Y; Papaluca T; Macdonald GA; Rowland J; Colman A; Stoove M; Lloyd AR; Thompson AJ
Med J Aust; 2023 Mar; 218(5):231-237. PubMed ID: 36871200
[TBL] [Abstract][Full Text] [Related]
5. Considering treatment-as-prevention scale-up for Australian prisons: a qualitative sub-study of expert stakeholders from the Australian 'surveillance and treatment of prisoners with hepatitis C' project (SToP-C).
Rance J; Lafferty L; Treloar C;
Harm Reduct J; 2021 Apr; 18(1):46. PubMed ID: 33902595
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP-C Treatment as Prevention Study in Prisons.
Lim AG; Stone J; Hajarizadeh B; Byrne M; Chambers GM; Martin NK; Grebely J; Dore GJ; Lloyd AR; Vickerman P
Hepatology; 2021 Nov; 74(5):2366-2379. PubMed ID: 34105797
[TBL] [Abstract][Full Text] [Related]
7. Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and practice assessment in Europe.
Stöver H; Meroueh F; Marco A; Keppler K; Saiz de la Hoya P; Littlewood R; Wright N; Nava F; Alam F; Walcher S; Somaini L
BMC Public Health; 2019 Jan; 19(1):30. PubMed ID: 30621658
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study.
Carson JM; Dore GJ; Lloyd AR; Grebely J; Byrne M; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Matthews GV; Hajarizadeh B;
Clin Infect Dis; 2022 Nov; 75(10):1809-1819. PubMed ID: 35362522
[TBL] [Abstract][Full Text] [Related]
9. Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting.
Lafferty L; Rance J; Grebely J; Dore GJ; Lloyd AR; Treloar C;
Int J Drug Policy; 2020 Mar; 77():102693. PubMed ID: 32045828
[TBL] [Abstract][Full Text] [Related]
10. Barriers and facilitators to hepatitis C (HCV) screening and treatment-a description of prisoners' perspective.
Crowley D; Van Hout MC; Lambert JS; Kelly E; Murphy C; Cullen W
Harm Reduct J; 2018 Dec; 15(1):62. PubMed ID: 30538000
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C in Australian prisons: a national needs assessment.
Mina MM; Herawati L; Butler T; Lloyd A
Int J Prison Health; 2016; 12(1):3-16. PubMed ID: 26933988
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy.
Skipper C; Guy JM; Parkes J; Roderick P; Rosenberg WM
Gut; 2003 Oct; 52(10):1500-4. PubMed ID: 12970145
[TBL] [Abstract][Full Text] [Related]
13. The role of social capital in facilitating hepatitis C treatment scale-up within a treatment-as-prevention trial in the male prison setting.
Lafferty L; Rance J; Dore GJ; Lloyd AR; Treloar C
Addiction; 2021 May; 116(5):1162-1171. PubMed ID: 33006784
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C treatment as prevention in the prison setting: Assessments of acceptability of treatment scale up efforts by prison correctional and health personnel.
Lafferty L; Rance J; Dore GJ; Grebely J; Lloyd AR; Treloar C;
Int J Drug Policy; 2021 Dec; 98():103379. PubMed ID: 34311138
[TBL] [Abstract][Full Text] [Related]
15. High rate of hepatitis C reinfection following antiviral treatment in the North East England Prisons.
Bhandari R; Morey S; Hamoodi A; Thompson C; Jones D; Hewett M; Hunter E; Taha Y; McPherson S
J Viral Hepat; 2020 Apr; 27(4):449-452. PubMed ID: 31749225
[TBL] [Abstract][Full Text] [Related]
16. The furthest left behind: the urgent need to scale up harm reduction in prisons.
Sander G; Murphy F
Int J Prison Health; 2017 Sep; 13(3-4):185-191. PubMed ID: 28914120
[TBL] [Abstract][Full Text] [Related]
17. Expert stakeholder perspectives on the acceptability of treatment-as-prevention in prison: a qualitative substudy of the 'Surveillance and Treatment of Prisoners with Hepatitis C' project (SToP-C).
Rance J; Lafferty L; Treloar C;
Addiction; 2021 Oct; 116(10):2761-2769. PubMed ID: 33751739
[TBL] [Abstract][Full Text] [Related]
18. Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison.
Lafferty L; Rance J; Grebely J; Lloyd AR; Dore GJ; Treloar C;
J Viral Hepat; 2018 Dec; 25(12):1526-1532. PubMed ID: 30141261
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework.
Akiyama MJ; Kronfli N; Cabezas J; Sheehan Y; Thurairajah PH; Lines R; Lloyd AR;
Lancet Gastroenterol Hepatol; 2021 May; 6(5):391-400. PubMed ID: 33857445
[TBL] [Abstract][Full Text] [Related]
20. Prisoners should not be left behind in HCV research and policies.
Moazen B; Stöver H; Dolan K; Jahn A; Neuhann F
Harm Reduct J; 2020 May; 17(1):33. PubMed ID: 32448290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]